drugset / Trial / NCT00537368
First Study of the Safety of CNTO 888 in Patients With Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if CNTO 888 is safe and to determine how long CNTO 888 stays in the body and what effects it might have on cancer tumors.
Timeline
- Start
- 2007-09
- Primary completion
- —
- Completion
- 2010-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carlumab | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | Carlumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Carlumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Carlumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Carlumab | Monoclonal antibody | 15 mg/kg | Intravenous |